Core Insights - North Chip Life Technology Co., Ltd. has officially listed on the STAR Market, marking the first medical IPO of the year and achieving a market capitalization exceeding 20 billion yuan shortly after its debut [1][2] - The company was founded by Dr. Song Liang, who identified a critical technology gap in cardiovascular precision diagnosis and has since developed innovative medical devices [1][3] - North Chip Life is the first domestic high-end medical device company to successfully list on the STAR Market since the resumption of the fifth set of listing standards [1][5] Company Background - Dr. Song Liang, born in 1982, graduated from Wuhan University and later obtained a Ph.D. in biomedical engineering from the University of Washington [2] - After returning to China, he established a research lab at the Shenzhen Institute of Advanced Technology and began focusing on clinical needs in cardiovascular disease treatment [2][3] - The company was founded in 2015 and has developed the first domestic FFR system based on MEMS sensors, addressing a significant market gap [3] Product Development - North Chip Life has developed a total of 17 products in the cardiovascular interventional medical device field, including FFR systems and IVUS systems, with clinical applications in over 1,000 hospitals globally [3][4] - The company achieved a market-leading position with its 60MHz high-definition IVUS product shortly after its approval in China [3] Financial Performance - The company reported revenues of 92.45 million yuan in 2022, with projections of 184 million yuan and 317 million yuan for 2023 and 2024, respectively [4] - North Chip Life turned a profit before its IPO, with a net profit of 49.44 million yuan in the first half of 2025, indicating growing recognition in the global market [4] Investment and Support - The company has attracted significant investment from notable venture capital and private equity firms, including Sequoia China and Qiming Venture Partners, reflecting strong confidence in its growth potential [6][9] - North Chip Life has successfully completed multiple funding rounds, with key investors supporting its strategic vision and product development [8][9] Market Context - The IPO of North Chip Life signals a reopening of the A-share market for medical companies, with several other firms also preparing for listings [11][13] - The recent trend indicates a growing interest in domestic medical innovations, with many companies seeking to capitalize on favorable market conditions [12][14]

Core Insights - The company, Shenzhen Beixin Life Technology Co., Ltd., has successfully completed its initial public offering and is now listed on the Sci-Tech Innovation Board, marking a significant milestone in its growth journey [2] - The company focuses on innovative and high-quality solutions for cardiovascular disease treatment, emphasizing its commitment to clinical and patient-centered approaches [2] Product Development - The core products, including the Intravascular Ultrasound (IVUS) system and the Fractional Flow Reserve (FFR) system, have entered the national special review process for innovative medical devices, which is expected to transform clinical practices in Percutaneous Coronary Intervention (PCI) [3] - The Pulsed Field Ablation (PFA) system for atrial fibrillation treatment is also in the special review process and is the first PFA product from China to be included in the late-breaking clinical trial at the European Society of Cardiology Congress [3] - The InsightPFA clinical research results have been published in the top cardiovascular journal, JACC, representing the first randomized controlled clinical study of nanosecond pulse PFA in the industry [3] Future Outlook - The medical device sector is entering a new cycle of innovation characterized by intelligence and precision, presenting a historic strategic opportunity for Chinese medical enterprises to develop into globally influential medical technology companies over the next decade [4] - The company aims to leverage the "Healthy China" strategy, maintaining its focus on cardiovascular precision intervention and striving for exceptional quality, thereby showcasing the strength of Chinese innovation to the world [4] - The company expresses a desire for investors to understand its value proposition and growth potential, highlighting the opportunity for shared long-term growth [4]

Core Mission - The company aims to transform scientific research into practical technology to benefit patients, focusing on innovative high-performance medical devices [1] - The mission is to improve life and health through innovation and quality, specifically targeting cardiovascular disease intervention [1] Product Development - The company has developed a comprehensive solution for precise intervention in coronary heart disease, including the FFR system and IVUS system [1] - The FFR pressure microcatheter, launched in 2020, is the first domestically approved product in China for measuring blood flow reserve, filling a significant gap in the market [4] - The IVUS system is the first domestically developed 60MHz high-definition product approved by the National Medical Products Administration, rapidly gaining market share since its launch in 2022 [5] Market Impact - The FFR product achieved a market share of 30.6% in the coronary artery direct measurement market within a year of its launch, with applications in approximately 1,000 hospitals globally [4] - The IVUS system has also been adopted in around 1,000 hospitals, becoming the leading domestic product in its category [5] Innovation and Technology - The company has established four core technology platforms, including micro-nano device development and high-performance medical hardware development [6] - It has developed nearly 20 products and ongoing projects, positioning itself as a "small giant" in the cardiovascular intervention sector with international influence [6] Recognition and Achievements - The company has applied for over 360 patents, with more than 180 granted, including over 80 invention patents [6] - It has received various accolades, including the "National Specialized and Innovative 'Small Giant' Enterprise" certification and the Shenzhen Science and Technology Progress Award for its FFR system [6]

Core Insights - The National Medical Products Administration of China emphasizes support for high-end medical device innovation, particularly in advanced medical imaging equipment, to address the growing global demand for cardiovascular disease treatment solutions [1] - Beixin Life, a domestic company focused on high-end medical device innovation, aims to develop high-performance interventional medical devices to tackle the significant public health issue of cardiovascular diseases [1][3] - The company has successfully developed and commercialized proprietary high-performance diagnostic equipment, contributing to the advancement of domestic high-end medical devices [1][3] Industry Overview - Coronary heart disease is recognized as a major health threat globally, with cardiovascular diseases being the leading cause of death in China [2] - China has the highest annual volume of percutaneous coronary intervention (PCI) procedures, with a trend towards precision treatment guided by advanced coronary functional and imaging technologies [2] - The reliance on imported devices and materials has historically dominated the market due to high R&D barriers and long return cycles [2] Company Achievements - Since its establishment in 2015, Beixin Life has developed a series of intelligent cardiovascular interventional solutions, including the first domestically approved IVUS and FFR systems [3][4] - The company has obtained over 20 Class III medical device registrations and successfully launched 11 products [3] - Beixin Life is the only domestic company with the technology to develop and manufacture 60MHz high-frequency micro-ultrasound transducers and MEMS pressure sensor modules [4] Market Potential - The cardiovascular device market is the second largest globally and is expected to grow rapidly over the next decade, with a significant patient population for coronary heart disease [7] - The number of PCI procedures in China is projected to increase from 1.906 million in 2024 to 4.298 million by 2030, with a compound annual growth rate of approximately 14.5% [7] - The precision PCI market in China is expected to grow from 2.04 billion yuan in 2022 to 9.42 billion yuan by 2030, with a compound annual growth rate exceeding 20% [7] Competitive Position - Beixin Life's FFR product captured 30.6% of the domestic market share shortly after its launch, while its IVUS product became the leading domestic option, reducing reliance on imports [8] - The company has successfully expanded its products to international markets, receiving positive feedback and achieving routine clinical use in multiple countries [8] - Beixin Life aims to enhance the synergy of its product system and adapt to international markets, thereby improving the global competitiveness of China's high-performance medical device industry [9]

Core Viewpoint - North Chip Life Technology Co., Ltd. is preparing for its IPO on the Sci-Tech Innovation Board, focusing on innovative medical devices in the cardiovascular precision intervention field [1] Company Overview - Established in 2015, North Chip Life specializes in high-performance active interventional devices for major diseases such as coronary heart disease and atrial fibrillation [1] - The company has developed key technologies, including the first domestically developed FFR system and a 60MHz high-speed IVUS system, breaking foreign monopolies [1] - Over ten products have been commercialized, with FFR and IVUS systems used in approximately 1,000 hospitals globally [1] Research and Development - North Chip Life has significantly increased R&D investment, establishing four technical platforms covering the entire chain from core sensor packaging to image analysis algorithms [1] - The company has applied for over 360 patents, with more than 180 granted, including over 80 invention patents and 14 PCT international patent applications [2] Financial Performance - Revenue figures for 2022, 2023, and 2024 are approximately 0.92 billion, 1.84 billion, and 3.17 billion respectively, with positive operating cash flow and narrowing losses [2] - Sales and management expense ratios are projected to decrease by about 21 percentage points and 26 percentage points respectively in 2024, indicating improved operational efficiency [2] Market Potential - The number of PCI procedures in China reached 1.636 million in 2023, expected to grow to 4.3 million by 2030, driving demand for the company's core products [3] - The precision PCI market in China is projected to grow from 2.04 billion in 2022 to 9.42 billion by 2030, with a compound annual growth rate exceeding 20% [3] Global Expansion - North Chip Life is the first domestic company to obtain EU CE/MDR certification for both FFR and IVUS products, with regular supply to countries like Germany, the UK, and Italy [2] - In 2024, overseas revenue reached approximately 38.83 million, a year-on-year increase of nearly 160% [2] Vision and Future Plans - The company aims to become a world-class medical technology enterprise with a long-lasting impact, focusing on technology accumulation, product matrix, and global layout [3] - With a solid R&D capability and high-performance product matrix, North Chip Life is positioned to become a representative enterprise in the high-end medical device sector in China [3]